Academic Title(s)

• Professor of Pharmacy Practice
• Associate Professor of Psychiatry

Administrative Title(s)

• Director of Pharmacotherapy

Bio

Chrisovalantis (Chris) Paxos, PharmD graduated from Ohio Northern University in Ada, Ohio in 2007 and completed residency training in psychiatric pharmacy at West Virginia University Hospitals and School of Pharmacy in Morgantown, West Virginia in 2008. He served as the pharmacotherapy specialist in psychiatric medicine at Cleveland Clinic Akron General from 2009-2019. He is a board-certified pharmacotherapy specialist and psychiatric pharmacist by the Board of Pharmacy Specialties. Dr. Paxos serves as the director of pharmacotherapy for the College of Pharmacy.

Educational Background

• Doctor of Pharmacy, Ohio Northern University, 2007
• Psychiatric Residency, West Virginia University Hospitals and School of Pharmacy, 2008

Courses

• OTC/Self-Care
• Introduction to Chronic Diseases
• Nephrology
• Endocrinology
• Advanced Cardiology
• Gastroenterology
• Neurology-Psychiatry
• Infectious Diseases
• Critical Care
• Immunology-Oncology
• Special Populations

Academic & Professional Activities

• Member, CPNP Foundation, 2021-present
• Chair and Editor, CPNP Psychiatric Pharmacotherapy Review Course, 2020-present
• Senior Editor, CPNP Psychiatric Pharmacotherapy Review Course, 2016-2020
• Member, State of Ohio Board of Pharmacy Rules Review Committee, 2016-2019
• Director, OSHP Educational Affairs Division, 2015-2017

Awards

• P3 Teacher of the Year, 2020
• P3 Teacher of the Year, 2018
• P3 Teacher of the Year, 2017
• P4 Core Faculty Preceptor of the Year, 2016
• P3 Teacher of the Year, 2014

Distinctions

• Preceptor of the Year, Ohio Society of Health-System Pharmacists, 2019
• Regional Preceptor of the Year, Cleveland Clinic Pharmacy Residency Program, 2018
• Health-System Pharmacists of the Year, Ohio Society of Health-System Pharmacists, 2016

Presentations

• Paxos C. Review of long-acting injectable antipsychotics and pharmacist administration. OPA Training Program for Long-Acting Injectables. Columbus, OH. September 2021.
• Paxos C. Treatment-resistant schizophrenia. Northcoast Behavioral Healthcare. Virtual presentation. June 2021.
• Paxos C. Sunshine on a cloudy day: an antidepressant pharmacotherapy overview. APN Spring Pharmacology Symposium. Virtual presentation. May 2021.
• Paxos C, Bird S. From rough seas to smooth sailing: navigating dementia pharmacotherapy. OAAPN Canton Chapter. Virtual presentation. May 2021.
• Paxos C. Psychotropic medications and pharmacogenetics. American Academy of Family Physicians Neurology and Behavioral Health Conference. Virtual presentation. November 2020.

Publications

• Paxos C, Emshoff JB. Neurobiology and pharmacotherapy. In: Halter MJ, editor. Varcarolis’ Foundations of Psychiatric-Mental Health Nursing: A Clinical Approach. 9th ed. St. Louis (MO): Elsevier;2022:37-62.
• Walkerly A, Paxos C. Serotonergic antidepressants’ effects on bone health. Current Psychiatry. 2021;20(9):45-9.
• Miller L, Paxos C. Obsessive-compulsive disorder: it’s never enough. In: Schwinghammer TL, Koehler JM, Borchert JS, Slain D, Park SK, editors. Pharmacotherapy Casebook: A Patient-Focused Approach. 11th ed. New York (NY): McGraw-Hill;2020:222-24.
• Paxos C, Teter CJ. Substance-related disorders. In: Chisholm-Burns MA, Schwinghammer TL, Malone PM, Kolesar JM, Lee KC, Bookstaver PB, editors. Pharmacotherapy: Principles and Practice. 5th ed. New York (NY): McGraw-Hill;2019:547-62.
• Soric MM, Paxos C, Dugan SE, Fosnight SM, Turosky JZ, Sadana P, Emshoff JB, Everly L, Snyder BM, Mistry BK, Bhat S, Unruh AE, Safi IM. Prevalence and predictors of benzodiazepine monotherapy in patients with depression: a national cross-sectional study. J Clin Psychiatry. 2019;80(4):18m12588.